Deep Vein Thrombosis

Clinical Trial Finder

Many patients with deep vein thrombosis are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer

Condition:   Venous Thrombosis and Pulmonary Embolism
Intervention:   Drug: Rivaroxaban (Xarelto, BAY 59-7939)
Sponsors:   Bayer;   Janssen Research & Development, LLC
Not yet recruiting - verified July 2016

RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism

Condition:   Venous Thromboembolism
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2016

A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants

Condition:   Cancer
Interventions:   Drug: Rivaroxaban;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   Bayer
Recruiting - verified July 2016

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Condition:   Transcatheter Aortic Valve Replacement
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Acetylsalicylic acid;   Drug: Clopidogrel
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified July 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsor:   Bayer
Recruiting - verified July 2016

Study of a Novel Thrombectomy Device to Treat Acute Iliofemoral Deep Venous Thrombosis

Condition:   Venous Thrombosis
Interventions:   Device: a manual spiral thrombus broken suction device;   Procedure: catheter-directed thrombolysis;   Drug: low-molecular-weight heparin calcium;   Drug: urokinase
Sponsor:   Xuzhou Medical College
Enrolling by invitation - verified July 2016

Preconditioning With Limb Ischemia for Subarachnoid Hemorrhage

Condition:   Ischemic Preconditioning
Intervention:   Other: ischemic conditioning group
Sponsor:   University of Miami
Recruiting - verified July 2016

Early Post-Marketing Study of ELIQUIS (Apixaban) in Mexico

Conditions:   Deep Vein Thrombosis;   Pulmonary Embolism
Intervention:   Drug: Apixaban
Sponsor:   Bristol-Myers Squibb
Recruiting - verified July 2016

AOP2014 in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.

Condition:   Polycythemia Vera
Intervention:   Drug: Pegylated-Proline-interferon alpha-2b
Sponsors:   AOP Orphan Pharmaceuticals AG;   PharmaEssentia (Co-Sponsor for USA)
Active, not recruiting - verified July 2016

Sequential Expansion of Comparative Effectiveness of Anticoagulants

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2016

The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage

Condition:   Atrial Fibrillation
Intervention:   Drug: Observational
Sponsor:   Boehringer Ingelheim
Completed - verified July 2016

Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis

Conditions:   Venous Thrombosis;   Neoplasms
Intervention:   Drug: Heparin, Low-Molecular-Weight
Sponsors:   Medical College of Wisconsin;   Blood Center of Wisconsin;   University of Minnesota - Clinical and Translational Science Institute;   Ohio State University
Recruiting - verified July 2016

Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism

Conditions:   Hypercortisolism;   Cushing Syndrome
Interventions:   Procedure: Adrenalectomy;   Other: Observation
Sponsors:   National Cancer Institute (NCI);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   CC-OADRIS
Recruiting - verified March 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified July 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin
Sponsor:   Bayer
Recruiting - verified July 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified July 2016

Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy

Conditions:   Deep Venous Thrombosis;   Pulmonary Embolism
Interventions:   Drug: Low dose nadroparin;   Drug: Intermediate dose nadroparin;   Drug: Low dose enoxaparin;   Drug: Intermediate dose enoxaparin;   Drug: Low dose dalteparin;   Drug: Intermediate dose dalteparin;   Drug: Fixed low dose tinzaparin;   Drug: Intermediate dose tinzaparin
Sponsors:   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);   Netherlands Organisation for Scientific Research;   Aspen Pharma;   CHU of Saint Etienne (sponsor of the French part of the study)
Recruiting - verified July 2016

Optimal Duration of Anticoagulation in Deep Venous Thrombosis

Conditions:   Deep Vein Thrombosis of Lower Limb;   Lower Extremity Deep Venous Thrombosis Recurrent
Intervention:   Drug: Sodium warfarin
Sponsor:   University of Padova
Completed - verified July 2016

Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)

Condition:   Ankylosing Spondylitis
Intervention:  
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified July 2016

The UNBLOCK Study: Utilization of Bivalirudin On Clots in Kids

Condition:   Deep Venous Thrombosis
Intervention:   Drug: Bivalirudin
Sponsors:   Children's Hospital Los Angeles;   Texas Children's Hospital;   Children's Hospital Colorado;   Children's Hospital of Philadelphia;   Nationwide Children's Hospital;   University of Texas Southwestern Medical Center
Completed - verified July 2016

Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer

Conditions:   Breast Cancer;   Colorectal Cancer;   Lung Cancer;   Prostate Cancer;   Veno-occlusive Disease
Interventions:   Drug: dalteparin;   Drug: standard therapy
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
Completed - verified July 2016